{"id":287444,"date":"2025-07-24T08:29:11","date_gmt":"2025-07-24T08:29:11","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/287444\/"},"modified":"2025-07-24T08:29:11","modified_gmt":"2025-07-24T08:29:11","slug":"could-starmers-brexit-reset-drag-the-cbd-industry-back-to-square-one","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/287444\/","title":{"rendered":"Could Starmer’s ‘Brexit Reset’ Drag the CBD Industry Back to Square One?"},"content":{"rendered":"

As part of the FSA\u2019s re-energised efforts to push forward with the long-running CBD novel foods approvals process, the agency hosted a meeting with industry stakeholders on Wednesday (July 23) to discuss upcoming negotiations which could have a major impact on the future of the industry.<\/p>\n

Under its largely overhauled new leadership, earlier this month the FSA provided some long-called-for clarifications on THC limits, ADI guidance, and prospective timelines<\/a> for businesses still waiting for their products to be officially approved by the regulators.<\/p>\n

However, Wednesday\u2019s consultation shifted its focus to the Starmer administration\u2019s efforts to secure a Sanitary and Phytosanitary (SPS) agreement with the European Union, with a view to boosting trade with the UK\u2019s closest trading partners.<\/p>\n

These complex negotiations are still in the early stages<\/a>, but depending on the outcome, could see the UK more closely align with EU regulations on CBD.<\/p>\n

While this could open up the EU market for UK-based CBD businesses, it could also push the process back even further given the union\u2019s current state of inaction.<\/p>\n

Many questions remain unanswered, and frustration among business owners is palpable, but the fact that the FSA called this meeting to inform the industry of potential risks as they develop represents a marked shift in transparency and active engagement from the regulator.<\/p>\n

What is an SPS Agreement?<\/strong><\/p>\n

An SPS Agreement is a type of international treaty that governs how countries apply health and safety regulations to protect humans, animals, and plants while preventing such rules from becoming hidden forms of trade protectionism.<\/p>\n

Overseen by the World Trade Organization (WTO), the SPS framework encourages countries to harmonise their rules with international standards, but does allow for flexibility to go beyond those standards if justified by scientific evidence.<\/p>\n

In May, the UK and European Commission met in Brussels for \u2018exploratory talks\u2019 into potential future bilateral trade and alignment<\/a>, part of Starmer\u2019s so-called \u2018Brexit reset\u2019 initiative.<\/p>\n

No concrete agreements were made during the meeting, but the groundwork was laid for future, more detailed negotiations into a number of areas, including an SPS Agreement.<\/p>\n

Proposals now on the table would see checks on plant produce, and other agrifood items removed, but both sides would rely on a \u2018dynamic alignment\u2019 mechanism, seeing the UK automatically adopt relevant EU rules.<\/p>\n

The UK could request limited exceptions to alignment, but only if:<\/p>\n

    \n
  1. a) It doesn\u2019t lower standards,<\/strong><\/li>\n
  2. b) It doesn\u2019t disadvantage EU products in the UK market,<\/strong><\/li>\n
  3. c) It doesn\u2019t compromise EU import rules.<\/strong><\/li>\n<\/ol>\n

    What does this mean for CBD?<\/strong><\/p>\n

    For all its missteps, the FSA\u2019s CBD novel food programme remains the only one in the world working to regulate CBD as a food.<\/p>\n

    In Europe, the European Food Safety Authority (EFSA) effectively \u2018stopped the clock\u2019<\/a> on the 19 European novel foods applications currently under consideration until \u2018many data gaps\u2019 on the health effects of CBD in humans have been filled.<\/p>\n

    Since then, almost no progress has been made on the part of the EFSA, who have called for more data, including human toxicology studies, to determine the safety of CBD.<\/p>\n

    This puts the UK and EU\u2019s CBD regulations at odds with each other, and despite efforts to edge the process towards official approvals in the UK, a comprehensive alignment with the EU could put the entire industry back to square one.<\/p>\n

    According to the FSA, there are three potential outcomes of these negotiations in regards to CBD, though it\u2019s worth noting that these are expected to be years away, and will reportedly not immediately impact the work they are doing on the public list and novel food applications.<\/p>\n

      \n
    1. Full dynamic alignment with the EU (no exceptions): The UK would follow EU rules for CBD, and market authorisations would be made by the EU for both the EU and Great Britain.<\/strong><\/li>\n
    2. Dynamic alignment with some exceptions (including a full exception for CBD): The UK would maintain an independent policy for CBD, and the FSA\u2019s CBD program would continue as planned.<\/strong><\/li>\n
    3. Failure to reach an agreement: The status quo would continue.<\/strong><\/li>\n<\/ol>\n

      For businesses that have already spent tens of thousands on their UK applications and waited in limbo for half a decade, handing the power back to the EFSA would be a painful twisting of the knife.<\/p>\n

      \u201cThe FSA remains committed to delivering the program to support market authorisations for CBD products,\u201d a representative told stakeholders.<\/p>\n

      \u201cTo do that in full, without changes, we would need an exception to be negotiated. But that outcome depends on factors beyond our control, namely the wider UK government\u2019s negotiating position and what agreement, if any, is reached with the EU.\u201d<\/p>\n

      The FSA explained that for the UK to secure any exception covering CBD products under an SPS deal, the EU had established three clear conditions.<\/p>\n

      \u201cFirst, any agreement must not lead to lower standards compared to EU rules. Second, it must not negatively impact imports from the EU having access to markets in the UK. And third, perhaps the most difficult to satisfy in practice, only goods that comply with EU rules can be allowed onto the EU market.\u201d<\/p>\n

      Even if these three tests are met, however, agreement is far from assured.<\/p>\n

      \u201cActually satisfying those tests doesn\u2019t guarantee agreement,\u201d the FSA added. \u201cIt\u2019s also important to understand that the EU won\u2019t want to give the UK what it sees as an unfair competitive advantage, or a better deal than member states, in any respect.\u201d<\/p>\n

      Looking ahead, the FSA was unable to offer any concrete roadmap, as it is not yet clear when negotiations will begin. However, representatives noted that the \u2018UK government wants to reach an SPS agreement as soon as possible, and negotiations are expected to take place in the next year.\u2019<\/p>\n

      Once any agreements are made, there is likely to be a \u2018substantial\u2019 transition period.<\/p>\n

      Although the FSA has clearly made a conscious effort to keep the industry informed of upcoming developments (not to mention this is out of their control), for CBD business owners this will create yet more uncertainty, complications, and worry.<\/p>\n

      \u00a0<\/p>\n

      \u00a0<\/p>\n

      To better understand the real-world impact of the FSA\u2019s CBD Novel Foods process, the Cannabis Trades Association (CTA) has launched a new industry-wide survey to gather insights from businesses operating in the CBD food sector.<\/p>\n

      Whether your company is still trading, has scaled back, exited the market, or was affected at any point since 2018, your experiences matter. The findings will be anonymised and used to inform the FSA and other stakeholders, supporting calls for a more balanced and effective regulatory environment.<\/p>\n

      \ud83d\udc49 Take the survey now<\/a><\/p>\n

      \"\"<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"As part of the FSA\u2019s re-energised efforts to push forward with the long-running CBD novel foods approvals process,…\n","protected":false},"author":2,"featured_media":287445,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5226],"tags":[802,748,75133,107396,2000,299,5187,1699,847,45582,4884,28564,107397,16,15],"class_list":{"0":"post-287444","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-brexit","8":"tag-brexit","9":"tag-britain","10":"tag-cbd","11":"tag-efsa","12":"tag-eu","13":"tag-europe","14":"tag-european","15":"tag-european-union","16":"tag-food-standards-agency","17":"tag-fsa","18":"tag-great-britain","19":"tag-kier-starmer","20":"tag-novel-foods","21":"tag-uk","22":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114907274675812922","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/287444","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=287444"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/287444\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/287445"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=287444"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=287444"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=287444"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}